Penumbra develops and markets medical devices for interventional neurology and vascular care, best known for systems that remove blood clots in stroke and other thromboembolic disease. Its portfolio also includes products for embolization, access and peripheral vascular procedures used in catheter-based interventions. Hospitals and specialists rely on these tools for acute stroke treatment and minimally invasive vascular therapy.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 324.1 | — | 39.2 | 142.1% |
| Q2 2025 | 339.4 | — | 45.3 | 82.5% |
| Q3 2025 | 354.7 | — | 45.9 | 38.9% |
| Q4 2025 | 385.4 | — | 47.3 | 27.2% |
| Q1 2026 | 374.8 | 15.6% | 32.6 | -16.9% |
| Q2 2026 | 390.1 | 14.9% | 34.8 | -23.1% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Equity LifeStyle Properties, Inc. (ELS), Crown Holdings, Inc. (CCK), Webster Financial Corporation (WBS), Graco Inc. (GGG), Gartner, Inc. (IT), Brown-Forman Corporation (BF A)